Adicet Bio, Inc. (FRA:1IJ)

Market Cap	61.25M -30.5%
Revenue (ttm)	n/a
Net Income	-98.03M
EPS	-17.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,983
Average Volume	n/a
Open	6.05
Previous Close	5.65
Day's Range	6.05 - 6.05
52-Week Range	5.15 - 15.20
Beta	n/a
RSI	49.56
Earnings Date	Mar 6, 2026

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodg...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 152
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1IJ

Financial Performance

Financial numbers in USD